Angiotensin receptor blockers for heart failure
23 results
1 - 23
ARB treatment of high CV risk patients- ACE inhibitor preferred over ARB in patients with ischemic heart disease
- SGLT2 inhibitors optimal drug class for heart failure with preserved and mildly reduced ejection fraction
- Valsartan/sacubitril reduces mortality more than enalapril 10 mg twice daily in patients with heart failure (PARADIGM-HF)
- Diagnosing and managing acute heart failure Guidelines: NICE
- Guideline for the management of heart failure: early prevention for patients at risk, quadruple therapy for those with symptoms
- ACE inhibitors decrease cardio events in patients with diabetes, ARBs don't
- For patients with AMI and preserved ejection fraction, long-term beta-blockers do not improve outcomes (REDUCE-AMI)
- Eplerenone reduces mortality in NYHA II heart failure
- No improved patient-oriented outcomes with sacubitril/valsartan in adults with heart failure and preserved EF (PARALLAX)
- Finerenone decreases hospitalization for heart failure in patients with type 2 diabetes and chronic kidney disease (NNT = 189/year)
- No differences in postoperative deaths or complications with stopping or continuing renin-angiotensin system inhibitors
- Bedtime instead of morning ingestion of hypertension meds = significantly more reduction in cardiovascular disease risk
- Compliance with heart failure performance measures not associated with improved outcomes
- JNC 8 report on prevention/evaluation/treatment of hypertension
- Finerenone reduces composite cardiovascular outcome and risk of decreased eGFR, but increases risk of hyperkalemia
- Dapagliflozin reduces mortality and renal replacement in patients with chronic kidney disease
- Rhythm control no better than rate control in AF + CHF
- Irbesartan slows aortic dilation, but doesn't reduce the rate of surgery in those with Marfan syndrome (AIMS)
- Antihypertensive therapy beneficial for patients with BP < 140/90 and history of CVD
- BP target of 120 no better than 140 in T2DM (ACCORD)
- SBP of 120 instead of 140 in nondiabetic, high-risk elderly leads to significant benefits and some harms (SPRINT)